| Prev Close | 66.21 |
| Open | 66.46 |
| Day Low/High | 66.45 / 67.32 |
| 52 Wk Low/High | 53.63 / 71.70 |
| Volume | 4.23M |
Astrazeneca PLC Sponsored ADR (AZN)
66.67
0.46
0.69
NASDAQ
| Exchange | NASDAQ |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
Wake Up Wall Street: Donald Trump to Address Congress
U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.
Global Financial News: Nikkei 225 Snaps Losing Streak
Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close
AstraZeneca Has Started a Turnaround
The old saying that volume precedes price could be playing out
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Cramer: Allergan Is the New Pharma Growth Stock
Jim Cramer compares Allergan's growth to other pharma stocks.
AstraZeneca Provides Cautious 2017 Guidance
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.
News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach
Here is a round-up of the headlines from Europe.
Bullish and Bearish Reversals in the Market
These companies show signs of a change of direction.
Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
AstraZeneca Reports Positive Lung Cancer Drug Trial Results
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
What to Watch This Week: Presidential Election, Mylan Earnings
For the week of November 7, all eyes will be on Tuesday's presidential election.
Cramer: Don't Just Stand There Like Bambi; Sell Some
Stocks in the health care sector seem to have no underpinnings whatsoever.
Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
Chi-Med Not Your Typical 'Binary Biotech' Says CEO
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
Cempra Is Ready to Run
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Big Pharma Has No Rx for Viral Social Media Reactions
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Portfolio Manager: Is Pfizer Acquiring Too Quickly?
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business
Pfizer is making another acquisition.
4 Stocks to Avoid Amid the Mad 'Search for Yield'
There's a price to pay for low expectations.
Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher
Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.
AstraZeneca Likely to Grind Lower
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.
Bret Jensen Reporting for Duty
Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...
2 Small-Cap Biotechs With Big Ambitions
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Relypsa's Still a Bargain Despite 67% Rally
Small biotech has plenty of cash and a very valuable drug.
Relypsa's Still a Bargain Despite 67% Rally
Small biotech has plenty of cash and a very valuable drug.
Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
Revisiting 3 Promising Small Biotechs
They are oversold and lately been on the move.
